metabolic syndrome and genotype 1 virus c compensated liver cirrhosis in the era of directly acting antiviral therapy

Objectives: the current study aimed at evaluating the association between metabolic syndrome (mes) in patients with hepatitis c virus (hcv) liver cirrhosis (compensated, genotype, 1b) and changes after sustained viral response (svr) following a 12-week therapy with paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin (prod+r). methods: the current multicenter retrospective study included 809 patients diagnosed with compensated hcv cirrhosis (child class a), all 1b genotype treated for 12 weeks with direct acting antiviral agents - prod+r - regimen (according to the protocol practiced in romania) and achieved svr. the parameters of mes (according to the definition of the international diabetes federation) were collected from medical records before and 12 weeks after the treatment. the results were collected in a central database and analyzed with spss 18.0. statistical analysis used both descriptive and analytical methods with a significance level of 95% (ci 95%). results: out of the 809 patients, 105 (13%) demonstrated 3 out of the 5 criteria for mes. based on the mes criteria, the commonest parameters were abnormal glycaemia (54.1%), followed by visceral obesity (38.6%), raised triglycerides (26.1%), high blood pressure (12.1%), and a low high-density lipoprotein (hdl)-cholesterol (4.6%). the re-assessment of mes parameters after svr showed favourable changes, which were statistically significant: a siginficanttly lower serum triglyeride level (182.32 vs. 153.50 mg/dl, p = 0.001), lower systolic arterial blood pressure (130.57 vs. 124.85 mmhg; p = 0.001), lower diastolic arterial blood pressure (80.26 vs. 78.42 mmhg; p = 0.001) and lower glyceamic levels (130.06 vs. 120.71 mg/dl; p = 0.001), as well as a significant rise in hdl-cholesterol levels (48.61 vs. 50.50 mg/dl; p = 0.003). abdominal circumference was the only parameter, which did not change after svr. following the changes sustained after svr, 26.7% of the patients no longer fulfilled the minimum 3 criteria for mes. no correlation was observed between the presence of mes and the risk of severe adverse events, but it was noted that 37.5% of the patients who decompensated, 66.7% of the ones who developed hepatocarcinoma and 100% of the ones that died of abnormal glycaemic levels. conclusions: hyperglycemia, and not mes, is associated with hcv compensated liver cirrhosis genotype 1b, and is a risk factor for severe adverse events. the attainment of svr through prod+r regimen results in short-term improvements in mes parameters.